Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Synopsys heads into its May 27 earnings report with options positioning notably more constructive than its recent norm — a clear break from the cautious stance that dominated the past month.
The clearest signal is in the put/call ratio. It has dropped to 0.90, more than one standard deviation below its 20-day average of 1.04, meaning traders have rotated away from the defensive hedges that were piling up through early May, when the PCR briefly touched its 52-week high of 1.21. The shift is striking: as recently as May 8, puts were running significantly heavier than calls; by this week, that protection has been actively unwound. Borrow conditions reinforce the benign backdrop — short interest has eased roughly 10% over the past month to 2.4% of free float, cost to borrow is a negligible 0.43%, and availability is effectively unconstrained. There is no meaningful pressure building in the lending market.
The stock has rallied to meet that positioning. Shares closed at $534.56 on Tuesday, up more than 8% on the week and 6.7% over the past month, and are now trading just below Rosenblatt's freshly raised target of $575. Closest peer Cadence Design Systems gained a similar 10.3% on the week, suggesting broad EDA sector tailwinds rather than SNPS-specific momentum. C3.ai also rallied hard (+9.6% on the week), while Microsoft lagged noticeably at -1.8%, highlighting that the bid has been concentrated in AI-adjacent software names.
The analyst picture has tilted positive heading into the print. Rosenblatt raised its target to $575 on the morning of earnings day, keeping its Buy. Citigroup lifted to $600 earlier in May, also maintaining Buy. Wells Fargo raised its target to $505 from $450, though it remains at Equal-Weight — a signal that even the sideliners are acknowledging upward estimate drift. The bull case centres on Synopsys's position at the intersection of AI-driven chip design complexity and accelerating EDA adoption, with margin improvement expected from recent cost discipline. Bears point to Intel customer concentration, rising in-house design activity among large fabless players, and China export restrictions that cap one of the company's key growth markets. Morgan Stanley's downgrade to Equal-Weight in late February — cutting its target to $480 from $550 — remains the most prominent dissenting voice, though the stock has since recovered well past those levels, partially undermining the bear thesis on price action alone.
Historical reactions offer a mixed guide. The most recent print on April 16 produced a clean +2.5% one-day move and a +4.2% five-day drift. Before that, two consecutive reports delivered declines of 3–5% on the day. The mean analyst target of $541 sits just above the current price of $534, leaving limited implied upside from consensus — which means the earnings report is less a referendum on whether Synopsys can grow and more a test of whether the AI chip design narrative can justify a valuation running at roughly 34x earnings and 25x EV/EBITDA after a strong recovery rally.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
